A study published yesterday in Cancer Chemotherapy and Pharmacology reports that pharmacokinetic (PK) and pharmacodynamic (PD) data from a randomized, double-blind, phase 3 clinical study show similarity between mAbxience’s proposed rituximab biosimilar, RTXM83, and its reference, MabThera, using a population PK model approach.
A study published yesterday in Cancer Chemotherapy and Pharmacology reports that pharmacokinetic (PK) and pharmacodynamic (PD) data from a randomized, double-blind, phase 3 clinical study show similarity between mAbxience’s proposed rituximab biosimilar, RTXM83, and its reference, MabThera (also marketed as Ritxuan in the United States), using a population PK model approach.
The study was conducted in patients with diffuse large B-cell lymphoma (DLBCL). Patients (n = 251) received intravenous doses of 375 mg/m2 of either the biosimilar candidate plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (n = 127) or MabThera plus CHOP (n = 124).
PK similarity between the 2 products was assessed by comparing predicted serum concentratoins over time, derived from a population PK model, which “allows the use of sparse data to accurately calculate PK parameters,” according to the authors. Additionally, the schedule of treatment for DLBCL, which includes 6 treatment cycles that include 1 dose of rituximab every 21 days, allows for numerous PK measurements.
The primary PK endpoints of the study were area under the concentration—time curve (AUC) and the maximum serum concentration (Cmax), levels of CD20+ and CD19+ B cells in peripheral blood were assessed for the PD evaluation, and anti-drug antibodies (ADAs) were assessed.
The authors report the following:
The authors conclude that RTXM83 and MabThera have similar PK and PD and, to their knowledge, this study is the first to investigate the population PK of a rituximab biosimilar with a large sample size of patients, serum concentration, and multiple cycles of treatment.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.